EssexBio

Essex-Bio Group

简繁 EN

ANNOUNCEMENTS & SHAREHOLDER INFORMATION

Normative Disclosure, Honest Communication

Date

Title

File

Times

2023-03-29

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 9 JUNE 2023 (or any adjournment thereof)

905

2023-03-29

NOTICE OF ANNUAL GENERAL MEETING

926

2023-03-29

PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS, ELECTION OF A NEW INDEPENDENT NON-EXECUTIVE DIRECTOR, TERMINATION OF THE EXISTING SHARE OPTION SCHEME, ADOPTION OF THE NEW SHARE OPTION SCHEME AND NOTICE OF ANNUAL GENERAL MEETING

951

2023-03-27

NEXT DAY DISCLOSURE RETURN

907

2023-03-21

NEXT DAY DISCLOSURE RETURN

883

2023-03-20

NEXT DAY DISCLOSURE RETURN

965

2023-03-17

NEXT DAY DISCLOSURE RETURN

937

2023-03-16

NEXT DAY DISCLOSURE RETURN

946

2023-03-15

NEXT DAY DISCLOSURE RETURN

964

2023-03-14

NEXT DAY DISCLOSURE RETURN

926

2023-03-13

NEXT DAY DISCLOSURE RETURN

900

2023-03-08

FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2022

897

2023-03-08

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2022

951

2023-03-02

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2023

904

2023-02-24

NOTICE OF BOARD MEETING

930

2023-02-22

UPDATE ON DISCLOSEABLE TRANSACTION AMENDMENT AGREEMENT TO THE CO-DEVELOPMENT LICENSE AGREEMENT WITH SHANGHAI HENLIUS BIOTECH, INC. FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION

913

2023-02-10

VOLUNTARY ANNOUNCEMENT FIRST PATIENT FIRST DOSE COMPLETED IN THE UNITED STATES IN AN INTERNATIONAL MULTI-CENTRE PHASE 3 CLINICAL STUDY IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS FOR THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

975

2023-02-02

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2023

943

2023-01-10

1032

2023-01-04

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2022

966

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT